drugset / Trial / NCT06455059

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

NCT06455059

Phase 3 Active not recruiting 80 enrolled BioMarin Pharmaceutical
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).

Timeline

Start
2024-06-17
Primary completion
2026-08-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vosoritide Peptide Subcutaneous

Indications